Description: With mortality rates significantly higher in 2020 and 2021 due to the COVID-19 pandemic, actuaries that rely on historical experience cannot properly craft assumptions about the future due to the recent excess deaths. This webcast focuses on the practicality of using pandemic mortality experience, as well as how to overcome the practical challenges of that data implementation. Explore an overview of different approaches used by institutions in the U.S., Canada and UK and an observation of industry survey responses. There will also be a comparison to recent SOA expert opinion surveys and short term impacts on the future of U.S. mortality.

Description: Term products exhibit a wide range of behavior as policyholders can elect different term periods and conversion options. While term products have been around for decades, it's only recently that longer level term products are reaching the end of the level term period. Term conversions have historically been an afterthought and are rarely modeled. Discuss the use of predictive modeling techniques such as LASSO regression and cross-validation to build models for level term lapses and post-level term shock lapses, as well as the extrapolation of experience for shorter term products to longer term products (e.g., extrapolating 20-year term experience and applying to 30-year term). Explore the use of traditional techniques to develop term conversion rates and a framework for modeling the assumption. Challenges and limitations of setting lapse and conversion rates will be discussed. By attending the session, you will: - Understand the complexities of term policyholder behavior. - Understand the challenges in developing and implementing assumptions for lapses and conversions. - Understand the application of traditional and predictive modeling techniques for term policyholder behavior.

Description: Oliver Wyman will share results from their recent Fixed and Index Annuity experience studies. Discuss fixed annuity dynamic lapse experience and learn about cross impacts of mortality and lapse on GLWB utilization. By attending the session, you will: - Understandg industry experience trends. - Comprehendindustry dynamic lapse experience for fixed and index annuity products. - Learn about areas of cross impacts of mortality, lapses and GLWB utilization.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: The most recent U.S. population data released by the Centers for Disease Control and Prevention (CDC) and from the U.S. Census at year-end 2021 includes the first ten months of the COVID-19 pandemic in the U.S. While we know the pandemic has had significant impacts on both the U.S. population and insured population mortality, we also see increased mortality due to many other non-COVID causes of death. Where are the biggest changes and what does this non-COVID excess mortality mean over the next few years? Take part as an expert panel hosts an interactive discussion to examine data from general population as well as from both individual life and group life experience studies to explore how these changes might spur innovation in underwriting, assumption setting and pricing.

Description: As the medicine practice continues to evolve, join us for this webcast to receive up-to-date information about the incorporation of scientific advancements and emerging evidence into the field. The creation of innovative treatments and the focus on improving patient outcome can cause information and price shocks, which will be one of the covered topics. Expect to utilize this webcast as an introduction to precision medicine, which is a genetics-based approach to healthcare. Speakers will share their experiences in demonstrating cost-effectiveness and promoting reimbursement with this new approach.

Description: Are you searching for an overview of the SOA Research Institute's Mortality & Longevity Strategic Research Program? Join us for an introduction into studies focusing on the historical U.S. population and insured mortality trends. Two research projects are observed in this webcast, one examining the impact of COVID-19 on mental illness and the impact of mental illness on U.S. Mortality & Longevity. The second study looks into the Group Life COVID-19 Mortality Survey and the high level view of U.S. group term life insurance mortality results during the pandemic. Come explore the research goals and the future for the Mortality & Longevity Strategic Program.

Description: The SOA has conducted a mortality study covering deferred annuities, both fixed and variable. This is a brand new area of analysis for the SOA's Individual Annuity Experience Committee and should be of critical interest to the industry. Previous industry annuitant mortality studies have focused on payout annuities, as well as the specialized structured settlement annuity market. Traditionally, mortality had not been seen as a critical assumption for deferred annuities. As the products have evolved over time, especially with the popularity of enhanced death benefits for variable annuities and guaranteed living benefits for both variable and fixed annuities, mortality has taken on increased importance. The results of this study have recently taken on even greater significance, as regulators are seeking mortality assumptions for the standard projection scenario for VM-22 (fixed annuities), as well as a potential update to those assumptions in VM-21 (variable annuities). By attending the session, you will: - Understand how deferred annuitant mortality compares with established annuitant mortality tables. Note that annuitant mortality tables, including the most recent 2012 tables, were developed based on payout annuitant mortality experience. - Become aware of the differences in mortality experience between fixed and variable annuities. - Gain insights into the effect of various guaranteed benefits on anti-selection and subsequent annuitant mortality, both for death benefits and living benefits. - Understand the durational aspects of emerging mortality experience, particularly for deferred annuities with guaranteed benefits.

Description: Anti-obesity medications have been met with reluctance from payers and employee benefits consultants who often lack analogs or empirical data to estimate the cost impact of new therapies coverage. Health plans considering coverage of anti-obesity medications will need to assess and manage the potential costs of covering these new therapies in context of their overall obesity management strategy, including coverage of nutrition counseling, weight management, and bariatric surgery.

Description: Dive into an overview of potential customer value propositions, trends in consumer acceptance and adoption, solving the data portability issue, potential impacts of emerging partner ships with OEMs and more within the auto insurance industry during our latest webcast. Experience interactive dialogue that will allow another dimension of thinking as industry experts provide insights and expertise. Throughout this webcast, you can expect developments in the personal lines automotive telematics-based insurance landscape that will develop a further understanding of the present and future of this industry.